Yahoo
    OTC Markets OTCPK - Delayed Quote USD

    Innovent Biologics, Inc. (IVBXF)

    10.60 -0.70 (-6.19%)
    As of October 30 at 4:00:00 PM EDT. Market Open.
    Loading Chart for IVBXF
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    View More
    Altruist Biologics' Integrated CMC Platform Supports NMPA Acceptance of NDA for Localized Manufacturing of Multinational Client's Biologic

    Altruist Biologics' Integrated CMC Platform Supports NMPA Acceptance of NDA for Localized Manufacturing of Multinational Client's Biologic
    PR Newswire 5d ago
    Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

    Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma
    PR Newswire 8d ago
    2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein

    2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein
    PR Newswire 8d ago
    2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer

    2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer
    PR Newswire 9d ago
    2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC

    2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC
    PR Newswire 9d ago
    Phase 3 Cancer Trial Win Could Be A Game Changer For Innovent Biologics Stock

    Phase 3 Cancer Trial Win Could Be A Game Changer For Innovent Biologics Stock
    Simply Wall St. 10d ago
    2026 ESMO LBA | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (CLDN18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of PFS and OS

    2026 ESMO LBA | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (CLDN18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of PFS and OS
    PR Newswire 11d ago
    2026 ESMO LBA | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (CLDN18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of PFS and OS

    2026 ESMO LBA | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (CLDN18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of PFS and OS
    PR Newswire 11d ago
    Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease

    Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease
    PR Newswire 25d ago
    Top China Biopharma Stocks to Watch, According to Bernstein

    Top China Biopharma Stocks to Watch, According to Bernstein
    Investing.com 1mo ago
    Innovent Biologics (SEHK:1801) Stock Still Looks Below Fair Value As Shares Rose 153%

    Innovent Biologics (SEHK:1801) Stock Still Looks Below Fair Value As Shares Rose 153%
    Simply Wall St. 1mo ago
    View More

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: